Epidemiological trends of neuroendocrine tumours over three decades in Queensland,Australia |
| |
| Institution: | 1. The Royal Brisbane and Women’s Hospital, Butterfield Street, Herston, Qld, 4029, Australia;2. Faculty of Medicine, The University of Queensland, 288 Herston Road, Herston, Qld, 4006, Australia;3. Cancer Alliance Queensland, Metro South Hospital and Health Service, 2 Burke St, Woolloongabba, Qld, 4102, Australia;1. Department of Experimental Medicine, Microbiology Section, University of Study of Campania “Luigi Vanvitelli”, Via De Crecchio, 7, 80138 Naples, Italy;2. Department of Woman, Child and of General and Specialized Surgery, University of Campania “Luigi Vanvitelli”, Largo Madonna delle Grazie, 1, 80138 Naples, Italy;1. Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital, The Capital Region, Nordre Fasanvej 57, 2000, Frederiksberg, Denmark;2. Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, Bethesda, MD, 20892-9778, USA;3. Novo Nordisk Foundation Center for Basic Metabolic Research, Section of Metabolic Genetics, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark;1. Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham AL, United States;2. O’Neal Comprehensive Cancer Center at University of Alabama at Birmingham, Birmingham AL, United States;3. College of Public Health, University of Kentucky, Lexington KY, United States;1. Department of Evolutionary Ecology, Doñana Biological Station, Consejo Superior de Investigaciones Científicas (CSIC), C/ Américo Vespucio 26, 41092 Sevilla, Spain;2. Laboratório de Genética, Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Av. Professor Egas Moniz, Edifício Egas Moniz, 1649-028 Lisboa, Portugal;3. Department of Dermatology, Virgen del Rocío University Hospital, Avda. Manuel Siurot s/n, 41013 Sevilla, Spain;1. Department of Epidemiology, Fielding School of Public Health, University of California, 10833 Le Conte Ave, Los Angeles, CA, 90095, USA;2. Danish Cancer Society Research Center, Strandboulevarden 49, 2100, Copenhagen, Denmark;3. Center for Occupational and Environmental Health, Fielding School of Public Health, University of California, 650 Charles E Young Drive, Los Angeles, CA, 90095, USA;4. Department of Clinical Epidemiology, Aarhus University, Olof Palmes Alle 43-45, 8200 Aarhus N, Aarhus, Denmark;1. Division of Public Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, and Huntsman Cancer Institute, Salt Lake City, UT, United States;2. International Agency for Research on Cancer, Lyon, France;3. Department of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA, United States;4. Institute of Population Health Sciences, National Health Research Institutes, Taiwan;5. Pôle Information Médicale Evaluation Recherche, Hospices Civils de Lyon, France;6. Division of Cancer Epidemiology and Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan;7. Department of Cancer Epidemiology, Nagoya University Graduate School of Medicine, Nagoya, Japan;8. Department of Epidemiology, School of Public Health, University of São Paulo, São Paulo, Brazil;9. Department of Head and Neck, Heliopolis Hospital, São Paulo, Brazil;10. Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;11. Department of Epidemiology, Gillings School of Global Public Health, Chapel Hill, NC, United States;12. Division of Head and Neck Surgical Oncology, Department of Otolaryngology/Head and Neck Surgery, Washington University School of Medicine, Saint Louis, MO, United States;13. Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Italy;14. Penn State College of Medicine, Hershey, PA, United States;15. University of Texas M. D. Anderson Cancer Center, Houston, TX, United States;p. Departments of Epidemiology and Environmental Health Sciences, School of Public Health, and Department of Urology, Medical School, University of Michigan, Ann Arbor, MI, United States;q. Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital (CHUV), Lausanne, Switzerland;r. College of Public Health, University of Iowa, Iowa City, IA, United States;s. Brown University, Providence, RI, United States;t. Fred Hutchinson Cancer Research Center, Seattle, WA, United States;u. Washington State University College of Pharmacy, Spokane, WA, United States;v. University of Heidelberg, Heidelberg, Germany;w. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, United States;x. Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy;y. Department of Otorhinolaryngology, School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy;z. Department of Biomedical and Clinical Sciences, University of Milan, Italy;1. Division of Epidemiology, New York University School of Medicine, New York, United States;2. Institute of Public Health, Section of Hygiene, Universita Cattolica del Sacro Cuore, Rome, Italy;3. Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy;4. Department of Head and Neck Surgery, Institute of Clinical Otorhinolaryngology, Università Cattolica del Sacro Cuore, Rome, Italy;5. Istituto di Clinica Otorinolaringoiatrica, Fondazione Policlinico Universitario A.Gemelli IRCCS, Rome, Italy;6. Cancer Research Centre, Moscow, Russia;7. Escola Nacional de Suade Publica, Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil;8. ACCAMARGO Cancer Center, São Paulo, Brazil;9. Institute of Oncology Angel H. Roffo, University of Buenos Aires, Argentina;10. Nofer Institute of Occupational Medicine, Lodz, Poland;11. Scientific Directorate, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Italy;12. National Institute of Health and Medical Research, Inserm U1018, Villejuif, France;13. Institute of Oncology and Radiobiology, Havana, Cuba;14. Universidade Federal de Pelotas, Pelotas, Brazil;15. Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil;P. National Institute of Public Health, Bucharest, Romania;Q. New York Eye and Ear Infirmary, New York, NY, United States;R. Department of Otolaryngology, School of Medicine, New York Medical College, Valhalla, NY, United States;S. The M. Skasodowska-Curie Memorial Cancer Center and Institute of Oncology, Dept. of Cancer Epidemiology and Prevention, Warsaw, Poland;T. Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany;U. Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany;V. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany;W. Regional Authority of Public Health in Banska Bystrica, Slovakia;X. National Institute of Environmental Health, Budapest, Hungary;Y. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States |
| |
| Abstract: | IntroductionWhile neuroendocrine tumours (NETs) account for only a small proportion of cancer diagnoses, incidence has been rising over time. We examined incidence, mortality and survival over three decades in a large population-based registry study.MethodsThis retrospective study included all cases (n = 4580) of NETs diagnosed from 1986 to 2015 in Queensland, Australia. We examined directly age-standardised incidence and mortality rates. The impact on overall survival according to demographic factors and primary site was modelled using multivariable Cox proportional hazards regression (HR). Cause-specific and relative survival were estimated using the Kaplan-Meier survival function.ResultsAnnual incidence increased from 2.0 in 1986 to 6.3 per 100,000 in 2015, while mortality remained stable. The most common primary site was appendix followed by lung, small intestine and rectum. Rectal, stomach, appendiceal and pancreatic NETs had the greatest rate increase, while lung NETs decreased over the same period. Five-year cause-specific survival improved from 69.4% during 1986–1995 to 92.6% from 2006 to 2015. Survival was highest for appendiceal and rectal NETs and lowest for pancreas and unknown primary sites. The risk of dying within five years of diagnosis was about 40% higher for males (HR = 1.41, 95%CI 1.20–1.65) and significantly higher for patients aged over 40 years compared to younger patients (p < 0.001).ConclusionThis study, including 30 years of data, found significantly increasing rates of NETs and confirms results from elsewhere. Increasing survival over time in this study, likely reflects increased awareness, improvements in diagnostic imaging, greater use of endoscopy and colonoscopy, and the development of new therapies. |
| |
| Keywords: | Neuroendocrine neoplasms Incidence Survival Population-based |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
